SINGAPORE, Sept. 25, 2018 /PRNewswire/ -- Holmusk, a
Singapore-headquartered digital
health and data analytics company with a global presence, today
announced closing of US$9.75
million in Pre-Series A financing. The financing round included
funding from Heritas Venture Fund as well as participation from new
and existing investors. The funds allow Holmusk to expand its
footprint in USA and Europe.
Holmusk leverages technology and data science to accelerate
research and improve outcomes for people with chronic diseases
and behavioral health
disorders. Partnering with Pharma and healthcare providers, Holmusk
informs predictive algorithms and provides actionable insights for
personalized medicine through its proprietary modelling platform.
Alongside this, it has an innovative digital health platform for
patient engagement.
"Holmusk's focus on promoting healthy lifestyles and addressing
chronic disease management made this an exciting opportunity to be
a part of," said Chik Wai Chiew, CEO
of Heritas Capital Management which oversees Heritas Venture Fund.
"Its approach of combining deep analytics with clinical research
and real-world data is promising and we are pleased to see the
company on track to build upon the successes of GlycoLeap and
SuperLeap and develop next generation versions in 2019."
Holmusk is also expanding its assets in behavioral health.
Having acquired MindLinc, a behavioral health EHR, it now
holds one of the largest behavioral health databases in the
world. Combining system dynamics with deep learning neural
networks and quantitative systems pharmacology, Holmusk is
developing MindLinc 2.0 which will include predictive disease
models based on longitudinal patient data.
Based out of Singapore, Holmusk
has offices in the US, UK and Malaysia. "Holmusk's technology platforms for
behavioral health and chronic diseases have global application and
we are excited about our expansion into USA and Europe. We look forward to sustaining the
momentum as we grow our client base around the world," said Kenneth
Ng, investor and Holmusk board chairman and co-founder/CIO
for NTAsset.
"I'm excited that we are entering this next stage of growth.
This financing reflects the trust our investors have in us and
gives us a healthy financial runway, which allows us to focus on
executing and growing aggressively in our core segments of chronic
disease management and behavioral health," Nawal Roy,
Founder and CEO explained. "The world is faced with
unprecedented health challenges and we're thrilled to play our part
in addressing them."
About Holmusk
Holmusk is a healthcare company on a mission to leverage
the power of human relationships, technology and data to prevent,
manage and reverse chronic disease and behavioral health issues. Our
proprietary modelling platform leverages scientific research and
digital healthcare data to inform predictive algorithms and provide
actionable insights for personalized medicine. We build innovative,
scalable and cost-effective digital behaviour change programs
(e.g. GlycoLeap) designed to nudge
people towards better health. For more information, visit: holmusk.com
View original
content:http://www.prnewswire.com/news-releases/holmusk-raises-us9-75-million-in-pre-series-a-financing-300718102.html
SOURCE Holmusk